Glenmark completes Phase-III trial of anti-diarrheal drug

The completion of the Phase-III trial was announced in the US by Glenmark's partners Napo Pharmaceuticals and Salix Pharmaceuticals, the company said in a filing to the Bombay Stock Exchange (BSE).

The trials are being conducted under a fast track status and has been a part of 'special protocol assessment'(SPA) agreement, it added.

"The results from these pivotal Phase-III studies for Crofelemer in the treatment of HIV associated diarrhea are very encouraging for Glenmark, as this will accelerate our goal to provide patients' access to this drug across multiple diarrheal conditions," Glenmark Pharmaceuticals Chief Executive Officer and Managing Director Glenn Saldanha said.
"We are encouraged by these results as we could now prepare for the launch of Crofelemer, and this will be our first novel product," he added.

The company plans to launch Crofelemer in 140 countries including India, for which it has exclusive marketing and distribution rights, it said.

Saldanha also said that the company plans to invest significant resources to fast track its development plan to ensure early regulatory approvals and launch in most of the markets.
Shares of Glenmark were today trading at Rs 372.50 on the BSE in the afternoon trade, up 2.35 per cent from its previous close.